Results 31 to 40 of about 19,810 (202)

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice [PDF]

, 2022
We evaluated virological response and resistance profile in virologically suppressed individuals switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real ...
Gennari, W, Borghi, V, Forbici, F, Andreoni, M, Gagliardini, R, Latini, A, Cicalini, S, Armenia, D, Berno, G, Lanini, S, Sarmati, L, Mussini, C, Santoro, M M, Bertoli, A, Santoro, M, Antinori, A, Perno, C F, Malagnino, V, Teti, E, Buonomini, A, Ceccherini-Silberstein, F, Ada Bertoli, Lanini, S., Giulia Berno, Loredana Sarmati, Gagliardini R., Forbici F., Borghi V., Vincenzo Malagnino, Santoro M. M., Federica Forbici, Ceccherini-Silberstein F., Vanni Borghi, Perno C. F., Massimo Andreoni, Carlo F. Perno, Buonomini A., Daniele Armenia, Malagnino V., Cicalini S., Andrea Antinori, Gennari W., Bertoli A., Sarmati L., Alessandra Latini, Andreoni M., Maria M. Santoro, Lanini S., Armenia D., Roberta Gagliardini, Teti E., Berno G., Francesca Ceccherini-Silberstein, Elisabetta Teti, Cristina Mussini, Latini A., Annarita Buonomini, Simone Lanini, Stefania Cicalini, Mussini C., Antinori A., William Gennari   +61 more
core   +1 more source

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B

Life, 2021
Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB.
Tomoya Sano, Takumi Kawaguchi, Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino, Takuji Torimura   +6 more
doaj   +1 more source

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

Clinical Case Reports, 2023
Key Clinical Message At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 109/L). Covid resolution and all “conventional” modifications were ineffective.
I. Vern Lim, Nurgül Özgür Yurttaş, Mesut Ayer, Şule Poturoğlu, Erdem Kınacı, İlgin Özden   +5 more
doaj   +1 more source

Tenofovir alafenamide clinical pharmacology

Infezioni in Medicina, 2021
Tenofovir today exists in two pharmaceutical forms, such as Tenofovir disoproxil fumarate (TDF) and the newer Tenofovir alafenamide (TAF). The two different salts are required in order to promote intestinal absorption of the active molecule (TFV).
openaire   +2 more sources

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Future Journal of Pharmaceutical Sciences, 2021
Background Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on ...
M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey   +2 more
doaj   +1 more source

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Drugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski   +6 more
doaj   +1 more source

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +1 more source

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis

Translation, 2023
Please view the PDF to see the formatted meeting abstract.
Abdulmajeed Alharbi
doaj   +1 more source